диссертации / 131

23.Albertsen, P. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer/ J. Hanley, D. Gleason, Р. Albertsen et al // JAMA.- 1998. – Vol.280. – P.975-980.

24.Alderson, D. Guidelines for the management of patients with pancreatic cancer

periampullary and ampullary carcinomas/ D. Johnson, J. Neoptolemos, D.

Alderson et al // Gut. - 2005. – Vol. 54 (Suppl 5), v.1–16.16.

25.Alexander, J. Cytokeratin profile of extrahepatic pancreatobiliary epithelia and their carcinomas/ S. Krishnamurthy, D. Kovacs, Y. Dayal, J. Aiexander // Appl Immunohistochem Mol Morphol. - 1997. – Vol.5. – P.216-222.

26.Allema, J. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region/ M. Reinders, T. van Gulik, M. Koelemay, J. Allema et al // Cancer. - 1995. – Vol. 75. – P. 2069-2076.

27.Allsbrook, J. W. The Gleason grading system: an overview/ K. Mangold, X. Yang, J.W. Allsbrook et al //J Urologic Path. – 1999. – Vol.10. – P.141-157.

28.Almoguera, C. Most humancarcinomas of the exocrine pancreas contain

mutant cKras genes/ D Shibata, K. Forrester, C. Almoguera et al // Cell. - 1988.

– Vol.53. – P.549–554.

29.American Cancer Society (ACS). Cancer Facts & Figures. //Atlanta. – 2013.

30.Andea, A. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma / F. Sarkar, V.Adsay, A. Andea // Mod Pathol. – 2003. - Vol. 16.

– P. 996-1006.

31. Anderson, K. Pancreatic cancer risk: associations with meat-derived carcinogen intake in the prostate, lung, colorectal, and ovarian cancer screening

101

trial (PLCO) cohort/ S. Mongin, R. Sinha, K. Anderson et al// Mol Carcinog. -

2012. – Vol. 51(1). – P.128–137.

32.Arslan, A.,Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium (PanScan)/ K. Helzlsouer, C. Kooperberg, A. Arslan et al //Arch Intern Med. - 2010. – Vol. 170(9). – P. 791–802.

33.Aune, D. Bodymass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies / D. Greenwood, D. Chan, R. Vieira, D. Aune et al. //Ann Oncol. - 2012.

– Vol. 23(4). – P. 843–852.

34. Bao, Y. Folate intake and risk of pancreatic cancer: pooled analysis of prospective cohort studies /D. Michaud, D. Spiegelman, D. Albanes, Y. Bao et al // J NatlCancerInst. – 2011. - Vol.103(24). – P.1840–1850.

35. Batge, B. Monoclonal antibodies against CEA-related components

discriminate between pancreatic duct type carcinomas and nonneoplastic duct lesions as well as nonduct type neoplasias / K. Bosslet, H. Sedlacek H., B. Batge et al //Virchows Arch A Pathol Anat Histopathol. - 1986. – Vol. 408. – P.361-374.

36.Bathe, O. Influence of Hispanic ethnicity on outcome after resection of carcinoma of the head of the pancreas / H. Caldera, K. Hamilton-Nelson, D. Franceschi, O. Bathe et al// Cancer. - 2001. – Vol. 91. - 1177-1184.

37.Benassai, G. Significance of lymph node metastases in the surgicamanagement of pancreatic head carcinoma / M. Mastrorilli, F. Mosella,G. Mosella, G. Benassai // J Exp Clin Cancer Res. - 1999. – Vol. 18. – P. 23-28.

38.Berger, A. The metastatic examined lymph node ratio is animportant prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma /

102

J. Watson, E. Ross, J. Hoffman, A. Berger// Am Surg. - 2004. – Vol. 70. – P. 235-

240.

39.Bosman, F.T. //WHO Classification of tumors of the digestive system/ F.T. Bosman // Lyon.-2010.-P.311.

40.Böttger, T. Relevant factors in the prognosis of ductal pancreatic carcinoma./ J. Zech, W. Weber, K. Sorger, Junginger, T. Böttger//Acta Chir Scand. - 1990. –

Vol. 156. – P. 781-788.

41. Bouvet, M. Factors influencing survival after resection for periampullary

neoplasms / R. Gamagami, E. Gilpin, O. Romeo, M. Bouvet //Am J Surg. - 2000. – Vol. 180. – P. 13-17.

42. Buhmeida, A.Nuclear Area is a Prognostic Determinant in Advanced

Colorectal Cancer/R. Ristamki, H. Lamlum, A. Buhmeida et al// Anticancer research. – 2005. – Vol.25.– P. - 3083-3088.

43. Cameron, J.Factors influencing survival after pancreaticoduodenectomy for

pancreatic cancer/D. Crist,J. Sitzmann, R. Hruban, J. Cameron et al// Am J Surg. - 1991. – Vol. 161. – P. 120-124.

44. Chari, S.Pancreatic cancer-associated diabetes mellitus: prevalenceand

temporal association with diagnosis of cancer /C. Leibson, K. Rabe, S. Chari et al// Gastroenterology. – 2008. – Vol. 134(1). – P. 95–101.

45. Chetty, R. Nuclear E-cadherin immunoexpression: from biology to potential applications in diagnostic pathology / S. Serra, R. Chetty // Adv Anat Pathol. – 2008. – Vol. 15. – P. 234-240.

103

46.Chetty, R. Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors / / S. Asa, S. Serra, R. Chetty // Am J Surg Pathol. - 2008. – Vol. 32. – P. 413-419.

47.Cubilla, A. Tumours of the Exocrine Pancreas/ Fitzgerald P., A. Cubilla // AFIP: Washington.- 1984.-P.312.

48.Devita, V. Cancer: Principles and practice of oncology 6- th ed/S. Hellman, S. Rosenberg,V. Devita et al // Philadelphia: Lippincott-Raven, 2001.-P.412.

49.Dong, M., Ma G., Tu W. et al. Clinicopathological significance of p53 and mdm2 protein expression in human pancreatic cancer/ G. Ma, W. Tu, M. Dong et al // World J. Gastroenterol. - 2005. – Vol. 11. – P. 2162–2165.

50.Duell, E. A population based, case control study of polymorphisms in carcinogen metabolizing genes, smoking, and pancreatic adenocarcinoma risk/E. Holly, P. Bracci, E. Duell et al// J Natl Cancer Inst. - 2002.-P. 356.

51.Dаbbs, D. Diagnostic Immunohistochemistry/ D. Dаbbs // Philadelphia, 2010.-P.426.

52.Eloubeidi, M. Prognostic factors for survival in pancreatic cancer: a populationbased study/ R. Desmond,C. Wilcox, M. Eloubeidi et al // Am J Surg. - 2006. – Vol. 192. – P. 322-329.

53.El-Serag, H. Risk of hepatobiliary and pancreatic cancer safter hepatitis C virus infection: apopulation-based study o U.S. veterans/ E. Engels, O. Landgren, E. Chiao, H. El-Serag et al // Hepatology. – 2009. – Vol. 49(1). – P.116–123.

54.Eskelinen, M.Prognostic factors in human pancreatic cancer, with special reference to quantitative histology/ P. Lipponen, M. Eskelinen et al // Scand J Gastroenterol. - 1991. – Vol. 26. – P. 483-490.

104

55. Esposito, I. Most Pancreatic Cancer Resections are R1 Resections / J. Kleeff F. Bergmann, I. Esposito // Annals of Surgical Oncology. – 2008. – Vol. 15(6). – P.1651–1660.

56.Esposito. I. Definition of Microscopic Tumor Clearance (R0) in Pancreatic Cancer Resections/ A. Schlitter,I. Esposito // Cancers. - 2010. – Vol. 2. - P. 20012010.

57.Ferell, L. Proposal for standardized criteria for the diagnosis of benign, borderline, and malignant hepathocellular lesions arising in chronic advanced liver disease / J. Crawford, A. Dhilon , L. Ferell et al //Am Surg Pathol. - 1993. – Vol.

17.– P. 1113-1123.

58.Fortner, J. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy /D. Klimstra, R. Senie, B. Maclean, J. Fortner // Ann Surg. – 1996. – Vol. 223. – P. 147-153.

59.Fuhrman, S. Prognostic significance of morphologic parameters in renal cell carcinoma / L. Lasky, C. Limas, S. Fuhrman //Am J Surg Pathol. – 1982. – Vol. 6(7). – P. 655-663.

60. Gansauge, F. Prognostic significance of molecular alterations in human

pancreatic carcinoma-an immunohistological study /S/ Gansauge, F. Gansauge et al // Langenbecks Arch Surg. - 1998. - Vol. 383(2). – P. 152-155.

61.Garcea, G. Survival Following Curative Resection for Pancreatic Ductal Adenocarcinoma. A Systematic Review of the Literature / A. Dennison, C. Pattenden, G. Garcea et al // JOP. J Pancreas/ - 2008. – Vol. 9(2). – P. 99-132.

62.Geer, R. Prognostic indicators for survival after resection of pancreatic adenocarcinoma /M. Brennan, R.Geer // Am J Surg. - 1993. – Vol. 165. – P. 68-

105

63.Genkinger, J. Coffee, tea, and sugar-sweeten edcarbonated soft drink intake and pancreatic cancer risk: a pooled analysis of 14 cohort studies/R. Li , D. Spiegelman , K. Anderson, J. Genkinger et al // Cancer Epidemiol Biomarkers Prev. - 2012. – Vol. 21(2). – P. 305–318.

64.Ghanch, P. Adenovirus–mediated transfer of p53 and p16 (INK4a) results in pancreatic cancer regression in vitro and in vivo/ W. Greenhalf, M. Humphreys, P. Ghanch et al //Gene Ther. - 2001. – Vol. 8(3). – P. 199–208.

65.Ghaneh, P. Biology and management of pancreatic cancer /E. Costello, J. Neoptolemos, P. Ghaneh // Gut. – 2007. – Vol. 56(8). – P. 1134–1152.

66.Gleason, D. Classification of prostate carcinomas / D. Gleason //Cancer Chemother Rep. – 1966. – Vol. 50. – P.125-128.

67. Gleason, D. Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging/ G. Mellinger, D. Gleason and the Veterans Administration Cooperative Urological Research Group // J Urol. – 1974. – Vol. 111. – P. 58-64.

68.Goldfarb, W. Carcinoma in heterotopic gastric pancreas/ D. Bennett, W. Monafo, W. Goldfarb //Ann Surg. – 1963. – Vol. 158. – P. 56-58.

69.Gong, Y. Gastrectomy and risk of pancreatic cancer: systematic review and meta-analysis of observational studies /Q. Zhou, Y. Zhou, Y. Gong et al // Cancer Causes Control. - 2012. – Vol. 23(8). – P. 1279–1288.

70.Greenblatt, M. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis /W. Bennett, M. Hollstein,C. Harris, M. Greenblatt // Cancer Res. - 1994. – Vol. 54. – P. 4855-4878.

106

71.Hahn, S. BRCA2 germ line mutations in familial pancreatic carcinoma/ B. Greenhalf, I. Ellis, S.Hahn et al// J Natl Cancer Inst. - 2003.-P.1267.

72.Hahn, S. Analysis of long-term survivors after surgical resection for pancreatic cancer/J. Jang J, S. Kim, S. Hahn et al // Pancreas. - 2006. – Vol. 32. – P. 271-275.

73.Hassan, M. Association between hepatitis B virus and pancreatic cancer/ D. Li, A. El-Deeb, M. Hassan et al //J Clin Oncol. - 2008. – Vol. 26(28). – P. 4557–

4562.

74.Hirata, K. Results of 1001 pancreatic resections for invasive ductal adenocarcinoma of the pancreas / T. Sato, M. Mukaiya, K. Hirata et al // Arch Surg. - 1997. – Vol. 132. – P. 771-776.

75.Hishinuma, S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings/Y. Ogata, M. Tomikawa, S. Hishinuma // J Gastrointest Surg. - 2006. – Vol. 10. – P. 511-518.

76.Howes, N. Clinical and genetic characteristics of hereditary pancreatitis in Europe/M. Lerch, W. Greenhalf, N. Howes for the European Registry of

77. Howes, N.Risk of pancreatic ductal adenocarcinoma in chronic pancreatitis/ J. Neoptolemos, N. Howes // Gut 2002. - 51765–766.766.

Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011.- SEER data submission, posted to the SEER web site.- 2012.

107

79.Howlade, N. SEER Cancer Statistics Review / A. Noone, M. Krapcho, N. Howlade et al. – 1975. -2010.

80.Hruban, R. Kras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant enriched polymerase chain reaction analysis and allele specific oligonucleotide hybridization/A. van Mansfeld,G. Offerhaus, R. Hruban et al // Am J Pathol. - 1993. - 143545–554.554.

81.Huxley, R. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies/ A. Ansary-Moghaddam, F. Barzi, M. Woodward, R. Huxley // Br J Cancer. - 2005. – Vol. 92(11). – P. 2076–2083.

82.Iodice, S. Tobacco and the risk of pancreatic cancer: a review and metaanalysis /S. Gandini, P. Maisonneuve, A. Lowenfels, S. Iodice // Langenbecks Arch Surg. - 2008. – Vol. 393(4). – P. 535–545.

83.Jansen, R. Meat-related mutagens and pancreatic cancer: null results from a clinic-based case-control study/ D. Robinson, R. Frank, R. Jansen et al // Cancer Epidemiol Biomarkers Prev. – 2013. – Vol.22 (7). – P.1336–1339.

84.Jansen, R. Fruit and vegetable consumption is inversely associated with having pancreatic cancer / D. Robinson, R. Stolzenberg-Solomon, R. Jansen et al // Cancer Causes Control. - 2011. – Vol. 22(12). – P.1613–1625.

85.Jansen, R. Nutrients from fruit and vegetable consumption reduce the risk of pancreatic cancer / D. Robinson, R. Stolzenberg-Solomon, R. Jansen et al // J Gastrointest Cancer. - 2013. – Vol. 44(2). – P.152–161.

Coldham, A. Mayer, N. Jarufe et al // Dig Surg. - 2004. – Vol. 21. – P. 202.

108

87. Jee, S. Fasting serum glucose level and cancer risk in Korean menand women / H. Ohrr, J. Sull. S. Jee // JAMA. – 2005. – Vol. 293(2). –P. 194–202.

88. Kayahara, M. Clinicopathological study of pancreatic carcinoma with

particular reference to the invasion of the extrapancreatic neural plexus / T. Nagakawa, I. Konishi, M. Kayahara // Int J Pancreatol. - 1991. – Vol. 10. – P.

105−111.

89. Kedra, B.Prognostic factors of long-term survival after resectiveprocedures for pancreatic cancer/T. Popiela, M. Sierzega, A. Precht, B. Kedra // Hepatogastroenterology. - 2001. – Vol. 48. - 1762-1766.

90. Kern, H. Fine structure of three major grades of malignancy of human

pancreaticadenocarcinoma / H. Roher, M. von Bulow, G. Kloppel, H. Kern // Pancreas. – 1987.- Vol. 2. – P. 2-13.

91. Kigure, S. Immunohistochemical study of the association between the

progression of pancreatic ductal lesions and the expression of MUC1, MUC2, MUC5AC, and E-cadherin / S. Kigure //Rinsho Byori. – 2006. – Vol. 54. – P. 447-452.

92.Kim G. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas / H. Bae, H. Park, G. Kim et al // Gastroenterology. - 2002. – Vol. 123. – P.1052-1060.

93.Klempnauer, J. Prognostic factors after resection of ampullary carcinoma: multivariate survival analysis in comparison with ductal cancer of the pancreatic head /G. Ridder, R. Pichlmayr, J. Klempnauer // Br J Surg. - 1995. – Vol. 82. –

P.1686-1691.

109

94.Klimstra, D. Ductal Proliferative Lesions Associated with Infiltrating Ductal Adenocarcinoma of the Pancreas / M. Hameed, A. Marrero, D. Klimstra et al // Int J Pancreatol. – 1994. – Vol.16. – P.224-225.

95.Kloppel, G. Histological and fine structural features of pancreatic ductal adenocarcinomas in relation to growth and prognosis: studies in xenografted tumours and clinico-histopathological correlation in a series of 75 cases / G. Lingenthal, M. von Bulow, H. Kern, G. Kloppel // Histopathology. - 1985. – Vol.

9.– P. 841-856.

96.Koushik, A. Intake of fruits and vegetables and risk of pancreatic cancer in a pooled analysis of 14 cohort studies / D. Spiegelman, D. Albanes, A. Koushik et al // Am J Epidemiol. - 2012. – Vol. 176(5). – P. 373–386.

97. Kuhlmann, K. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients / S. de Castro, J. Wesseling J, K. Kuhlmann et al // Eur J Cancer. - 2004. – Vol. 40. – P. 549-558.

98.Larsson, S. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis / E. Giovannucci, A. Wolk, S. Larsson // Gastroenterology. - 2006. – Vol. 131(4). – P. 1271–1283.

99.Larsson, S. Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies /A. Wolk, S. Larsson // Br J Cancer. –

2012. – Vol. 106(3). – P. 603–607.

100. Li, M. CDX-2, a new marker for adenocarcinoma of gastrointestinal origin / A. Folpe, M. Li //Adv Anat Pathol. – 2004. – Vol.11. – P.101-105.

101. Lim, J. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients / M. Chien, C. Earle, J. Lim // Ann Surg. - 2003. – Vol. 237. – P. 74-85.

110